每年在市场上建立的新药产生用于选择性生物靶向的特定结构。有了对分子识别的医学见解,这些分子为设计潜在的新药分子打开了新的空间。在这次审查中,我们报告了总共56种药物的汇编和分析,其中包括33种有机小分子(Mobocertinib,Infigratinib,Sotorasib,Trilaciclib,Umbralisib,Tepotinib,Relugolix,Pralsetinib,地西他滨,Ripreinib,Selpercatinib,卡马替尼,Pemigatinib,Tucatinib,Selumetinib,Tazemetostat,Avapritinib,扎努布替尼,恩替尼,佩西达替尼,达鲁他胺,Selinexor,Alpelisib,Erdafitinib,Gilteritinib,Larotrectinib,Glasdegib,洛拉替尼,Talazoparib,达科替尼,Duvelisib,Ivosidenib,阿帕鲁胺),6金属配合物(Edotreotide镓Ga-68,氟雌二醇F-18,Cu64dotatate,镓68PSMA-11,PiflufolastatF-18,177Lu(锶),16个大分子作为单克隆抗体缀合物(Brentuxiximabvedotin,Amivantamab-vmjw,隆卡妥昔阿替西林,Dostarlimab,马杜昔单抗,Naxitamab,Belantamabmafodotin,Tafasitamab,Inebilizumab,SacituzumabGovitecan,伊沙妥昔单抗,曲妥珠单抗,Enfortumabvedotin,Polatuzumab,Cemiplimab,Mogamulizumab)和1肽酶(Erwiniachrysanthemi衍生的天冬酰胺酶)在2018年至2021年间获得美国FDA批准。这些药物作为抗癌药物对抗各种癌症类型,尤其是非小细胞肺,淋巴瘤乳房,前列腺,多发性骨髓瘤,神经内分泌肿瘤,子宫颈,膀胱,胆管癌,髓系白血病,胃肠,神经母细胞瘤,甲状腺,上皮样和皮肤鳞状细胞癌。审查包括关键的结构特征,批准时间,目标选择性,行动机制,治疗适应症,配方,以及这些批准药物的可能合成方法。这些关键的细节将有利于科学界在这个领域的未来发展。
New drugs being established in the market every year produce specified structures for selective biological targeting. With medicinal insights into molecular recognition, these begot molecules open new rooms for designing potential new drug molecules. In this review, we report the compilation and analysis of a total of 56 drugs including 33 organic small molecules (Mobocertinib, Infigratinib, Sotorasib, Trilaciclib, Umbralisib, Tepotinib, Relugolix, Pralsetinib, Decitabine, Ripretinib, Selpercatinib, Capmatinib, Pemigatinib, Tucatinib, Selumetinib, Tazemetostat, Avapritinib, Zanubrutinib, Entrectinib, Pexidartinib, Darolutamide, Selinexor, Alpelisib, Erdafitinib, Gilteritinib, Larotrectinib, Glasdegib, Lorlatinib, Talazoparib, Dacomitinib, Duvelisib, Ivosidenib, Apalutamide), 6 metal complexes (Edotreotide Gallium Ga-68, fluoroestradiol F-18, Cu 64 dotatate, Gallium 68 PSMA-11, Piflufolastat F-18, 177Lu (lutetium)), 16 macromolecules as monoclonal antibody conjugates (Brentuximabvedotin, Amivantamab-vmjw, Loncastuximabtesirine, Dostarlimab, Margetuximab, Naxitamab, Belantamabmafodotin, Tafasitamab, Inebilizumab, SacituzumabGovitecan, Isatuximab, Trastuzumab, Enfortumabvedotin, Polatuzumab, Cemiplimab, Mogamulizumab) and 1 peptide enzyme (Erwiniachrysanthemi-derived asparaginase) approved by the U.S. FDA between 2018 to 2021. These drugs act as anticancer agents against various cancer types, especially non-small cell lung, lymphoma, breast, prostate, multiple myeloma, neuroendocrine tumor, cervical, bladder, cholangiocarcinoma, myeloid leukemia, gastrointestinal, neuroblastoma, thyroid, epithelioid and cutaneous squamous cell carcinoma. The review comprises the key structural features, approval times, target selectivity, mechanisms of action, therapeutic indication, formulations, and possible synthetic approaches of these approved drugs. These crucial details will benefit the scientific community for futuristic new developments in this arena.